Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -951 Thousand USD | 35.03% |
| 2021 | -1.02 Million USD | -99.61% |
| 2020 | -5.99 Million USD | 10.65% |
| 2019 | -122 Thousand USD | 70.87% |
| 2018 | -705 Thousand USD | -141.65% |
| 2017 | -5.85 Million USD | 85.7% |
| 2016 | -3.16 Million USD | 8.59% |
| 2015 | -6.04 Million USD | 10.62% |
| 2014 | -6.97 Million USD | -9.34% |
| 2013 | -6.37 Million USD | 6.96% |
| 2012 | -6.89 Million USD | -9.17% |
| 2011 | -5.69 Million USD | -51.95% |
| 2010 | -4.23 Million USD | -18.1% |
| 2009 | -4.63 Million USD | -6.75% |
| 2008 | -3.27 Million USD | -378.63% |
| 2007 | -684.23 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -134 Thousand USD | -28.85% |
| 2023 Q2 | -109 Thousand USD | 18.66% |
| 2022 FY | - USD | 35.03% |
| 2022 Q1 | -150 Thousand USD | 67.46% |
| 2022 Q3 | -126 Thousand USD | 55.63% |
| 2022 Q2 | -284 Thousand USD | -89.33% |
| 2022 Q4 | -104 Thousand USD | 17.46% |
| 2021 Q1 | -190 Thousand USD | -40.74% |
| 2021 Q2 | -156 Thousand USD | 17.89% |
| 2021 Q3 | -215 Thousand USD | -37.82% |
| 2021 Q4 | -461 Thousand USD | -114.42% |
| 2021 FY | - USD | -99.61% |
| 2020 Q3 | -137 Thousand USD | -19.13% |
| 2020 Q4 | -135 Thousand USD | 1.46% |
| 2020 FY | - USD | 10.65% |
| 2020 Q1 | -125 Thousand USD | -120.8% |
| 2020 Q2 | -115 Thousand USD | 8.0% |
| 2019 Q1 | -485 Thousand USD | 82.18% |
| 2019 Q4 | 601 Thousand USD | 155.09% |
| 2019 Q2 | 402 Thousand USD | 182.89% |
| 2019 Q3 | -1.09 Million USD | -371.39% |
| 2019 FY | - USD | 70.87% |
| 2018 Q1 | -535 Thousand USD | -110.27% |
| 2018 FY | - USD | -141.65% |
| 2018 Q4 | -2.72 Million USD | -222.79% |
| 2018 Q3 | 2.21 Million USD | 340.09% |
| 2018 Q2 | -923 Thousand USD | -72.52% |
| 2017 FY | - USD | 85.7% |
| 2017 Q4 | 5.2 Million USD | 327.57% |
| 2017 Q3 | -2.28 Million USD | -102.21% |
| 2017 Q2 | -1.13 Million USD | 56.5% |
| 2017 Q1 | -2.6 Million USD | 2.25% |
| 2016 Q2 | -918 Thousand USD | 41.27% |
| 2016 Q1 | -1.56 Million USD | -19.13% |
| 2016 FY | - USD | 8.59% |
| 2016 Q3 | -549 Thousand USD | 40.2% |
| 2016 Q4 | -2.66 Million USD | -384.88% |
| 2015 Q2 | -1.52 Million USD | 16.97% |
| 2015 FY | - USD | 10.62% |
| 2015 Q4 | -1.31 Million USD | 4.16% |
| 2015 Q3 | -1.36 Million USD | 10.29% |
| 2015 Q1 | -1.83 Million USD | -11.8% |
| 2014 Q2 | -1.6 Million USD | 17.27% |
| 2014 FY | - USD | -9.34% |
| 2014 Q3 | -1.78 Million USD | -11.81% |
| 2014 Q4 | -1.64 Million USD | 8.11% |
| 2014 Q1 | -1.93 Million USD | 5.61% |
| 2013 Q1 | -1.52 Million USD | 32.77% |
| 2013 FY | - USD | 6.96% |
| 2013 Q4 | -2.04 Million USD | -54.06% |
| 2013 Q3 | -1.33 Million USD | 33.43% |
| 2013 Q2 | -1.99 Million USD | -30.93% |
| 2012 FY | - USD | -9.17% |
| 2012 Q3 | -1.48 Million USD | 41.42% |
| 2012 Q4 | -2.26 Million USD | -52.55% |
| 2012 Q2 | -2.54 Million USD | -81.86% |
| 2012 Q1 | -1.39 Million USD | -1.93% |
| 2011 Q1 | -797.26 Thousand USD | 39.54% |
| 2011 Q2 | -1.68 Million USD | -110.78% |
| 2011 Q4 | -1.37 Million USD | 30.29% |
| 2011 FY | - USD | -51.95% |
| 2011 Q3 | -1.96 Million USD | -16.98% |
| 2010 Q3 | -566.81 Thousand USD | 62.25% |
| 2010 Q2 | -1.5 Million USD | -102.35% |
| 2010 Q4 | -1.31 Million USD | -132.66% |
| 2010 FY | - USD | -18.1% |
| 2010 Q1 | -741.94 Thousand USD | 59.95% |
| 2009 Q4 | -1.85 Million USD | -28.05% |
| 2009 Q2 | -852.4 Thousand USD | -68.67% |
| 2009 FY | - USD | -6.75% |
| 2009 Q1 | -505.38 Thousand USD | 62.01% |
| 2009 Q3 | -1.44 Million USD | -69.73% |
| 2008 Q2 | -506.93 Thousand USD | 3.55% |
| 2008 Q4 | -1.33 Million USD | -51.76% |
| 2008 Q3 | -876.65 Thousand USD | -72.93% |
| 2008 FY | - USD | -378.63% |
| 2008 Q1 | -525.59 Thousand USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.661% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 83.96% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.517% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 94.525% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.011% |
| Mesoblast Limited | -62.38 Million USD | 98.476% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 38.088% |
| Genus plc | 73.7 Million USD | 101.29% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 85.616% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 73.189% |
| Marizyme, Inc. | -34.28 Million USD | 97.226% |
| ContraFect Corporation | -64.99 Million USD | 98.537% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 89.159% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 78.989% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 32.159% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 64.038% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 59.076% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -83.574% |
| Accustem Sciences Inc. | -3.74 Million USD | 74.616% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.028% |
| EV Biologics, Inc. | -1.26 Million USD | 24.949% |
| Q BioMed Inc. | -617.62 Thousand USD | -53.976% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 126.624% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -50.378% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 58.371% |
| Biomind Labs Inc. | -1.03 Million USD | 8.076% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 109.628% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 86.72% |
| Skye Bioscience, Inc. | -13.54 Million USD | 92.98% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 36.063% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -3704.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 75.517% |
| IMV Inc. | -35.52 Million USD | 97.323% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 94.007% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 61.99% |
| GB Sciences, Inc. | -1.41 Million USD | 33.023% |
| Alpha Cognition Inc. | -9.7 Million USD | 90.202% |
| HST Global, Inc. | -5303.00 USD | -17833.245% |
| CSL Limited | 4.78 Billion USD | 100.02% |
| Halberd Corporation | -74.27 Thousand USD | -1180.308% |
| Enzolytics Inc. | -2.12 Million USD | 55.184% |
| Resverlogix Corp. | -11.74 Million USD | 91.901% |
| Affymax, Inc. | -14.29 Million USD | 93.347% |
| SYBLEU INC | -141.57 Thousand USD | -571.748% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 68.952% |
| argenx SE | -216.02 Million USD | 99.56% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.282% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 178.143% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 36.554% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 351.027% |
| AVAX Technologies, Inc. | -6.11 Million USD | 84.442% |
| Zenith Capital Corp. | -8.6 Million USD | 88.95% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.618% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5358.929% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 61.128% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -440.266% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.601% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 67.12% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 9.109% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 14243.367% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 45.657% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 50.492% |
| BioStem Technologies, Inc. | -7.55 Million USD | 87.41% |
| ONE Bio Corp. | 13.61 Million USD | 106.986% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -425.159% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 53.768% |
| Agentix Corp. | -1.37 Million USD | 30.673% |
| LadRx Corporation | 412.28 Thousand USD | 330.667% |
| Cell Source, Inc. | -4.27 Million USD | 77.742% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -158.972% |
| Regen BioPharma, Inc. | 1.46 Million USD | 164.872% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1.5% |
| NovAccess Global Inc. | -1.03 Million USD | 8.098% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 110.741% |
| Itoco Inc. | -1.86 Million USD | 49.117% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -150.514% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 14.785% |
| Kadimastem Ltd | -2.62 Million USD | 63.763% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -297.658% |
| CytoDyn Inc. | -18.02 Million USD | 94.725% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1103.356% |
| Mobile Lads Corp. | -2.24 Million USD | 57.567% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -7676.597% |
| Qrons Inc. | -40.08 Thousand USD | -2272.695% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -95.809% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 280.307% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 10.453% |
| International Stem Cell Corporation | 202 Thousand USD | 570.792% |
| Bioxytran, Inc. | -3.82 Million USD | 75.106% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1706.611% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 61.372% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 97.349% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2013.333% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 65.267% |
| Neutra Corp. | -181.24 Thousand USD | -424.698% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 95.283% |
| PureTech Health plc | -11.62 Million USD | 91.821% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 95.282% |
| IXICO plc | -707 Thousand USD | -34.512% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 87.625% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.033% |
| CSL Limited | 4.73 Billion USD | 100.02% |
| Cellectis S.A. | -92.63 Million USD | 98.973% |